FRANK P.

DELUCIA, MS
Raleigh NC 27614
919-270-3063 fpdintl@aol.com

A professional with sixteen years of experience with strong strategic planning and financial analytical,

reporting skills, who can draw from multiple global experiences and effectively lead cross functional groups
to generate immediate results and value.
WORK EXPERIENCE
Director Strategic Analysis, BioSolutions Services, Boston, MA
Oct 14 to Present
Consulting firm assisting global biopharmaceutical companies develop and commercialize biologic therapeutic products.
Current assignments: (1) Apply lessons learned from previous experience and develop strategic and financial
evaluation to support launch of new biologic drug. (2) Identify parties interested in acquiring a privately owned
Govt pricing, reporting, rebate service business.
Conducted financial audit of client contracts, restructured agreements delivering $176K of incremental profits.
VP Business Operations, Bio Products Laboratory USA Inc., Raleigh, NC
Jun 11 to Sept 14
European based manufacturer and global distributor of plasma derive products with global sales ~$200M, staff 500+.
Executed business strategy establishing a new US division for launching a new biotherapeutic drug. Responsible for
implementing and managing financial analysis and reporting, supply chain, accounting, reimbursement, and
administrative activities.
Coordinated sales strategies and generated $40M sales post 3 years launch targeting physicians, specialty
pharmacies, hospitals and secured federal and state government contracts for additional outlets.
Directed business development actions establishing a supply chain network. Secured multiple contracts:
7 key national distributors, 10 group purchasing organizations, 3PL service.
Built an integrated financial analysis & reporting system to support accounting transactions, business performance,
KPIs, effective budgeting, forecasting, inventory DoH management, and financial statements.
Developed a financial assessment process to evaluate on-going projects. Saved $2.5M in project cost.
Consultant, Pharmacision LLC, Ann Arbor, MI
May 10 to May 11
Formed start-up biotherapeutic consulting business targeting emerging life science companies.
Applied industry knowledge to develop realistic DCF financial model for evaluating new pipeline opportunity.
Hired to support development of US start-up strategy. Led to full-time position at Bio Products Laboratory.
Director Strategic Planning, Bus Develop, Talecris Biotherapeutics/Bayer Biologics, RTP, NC
A global manufacturer and distributor of plasma derived biotherapeutic therapies. Global sales >$1.B, staff 1,500+.
Talecris Biotherapeutics
Apr 05 to Apr 10
Financially evaluated and successfully executed strategy to acquire plasma collection business, value $125M.
Directed project management office (35 projects) to integrate business platforms. Achieved operating
efficiencies and increased volume throughput resulting in $15M incremental Gross Margin.
Developed, implemented new financial analysis process to guide investment decisions based on staged-gating
reviews and evaluations followed by a project prioritization process applying standardized criteria, (strategic,
technical, commercial, risks) and harmonizing financial valuations.
Bayer Biologics
Jun 99 to Apr 05
Responsible for global financial reporting and analysis including budgeting and long-range business forecasting.
Directed a cross functional effort rolling-out a revised global therapeutic-driven strategic plan. Actions
centered on successfully improving market share, therapeutic segment leadership, profit and cash flows.
Directed Business Development strategy leveraging industry network to secure portfolio and technology deals.
Value range $75 - $200M.
Led effort identifying a best fit joint venture and/or acquisition candidate. Combined value with M&A candidate,
#2 market leader, designated centers of manufacturing excellence, revenue growth $900M to $2.5B, synergies up
to $350M. Active participate in due diligence process and managed financial modeling.
Developed and presented divisional divestiture proposal to Healthcare executives following Board decision
not to pursue. Recommendation accepted, business sold ~$350M (renamed Talecris Biotherapeutics).

PROFESSIONAL DEVELOPMENT / EDUCATION

-

Executive Management Program University of Notre Dame, Illinois

Fairleigh Dickerson University Pharmaceutical Management Program
Masters in Accounting University of New Haven, Connecticut
Bachelor of Science, Administration University of New Haven, Connecticut